These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2959486)

  • 1. Cyclic hormonal treatment in ovarian cancer. A phase-II trial.
    Jakobsen A; Bertelsen K; Sell A
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):915-6. PubMed ID: 2959486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
    Hamerlynck JV; Maskens AP; Mangioni C; van der Burg ME; Wils JA; Vermorken JB; Rotmensz N
    Gynecol Oncol; 1985 Nov; 22(3):313-6. PubMed ID: 2998957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
    Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
    Gundersen S; Kvinnsland S; Lundgren S; Klepp O; Lund E; Børmer O; Høst H
    Breast Cancer Res Treat; 1990 Nov; 17(1):45-50. PubMed ID: 2151369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma.
    Riippa P; Kauppila A; Sundström H; Vihko R
    Anticancer Res; 1984; 4(3):109-12. PubMed ID: 6235770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study.
    Aabo K; Pedersen AG; Haid I; Dombernowsky P
    Cancer Treat Rep; 1982 Feb; 66(2):407-8. PubMed ID: 6459846
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro.
    Geisinger KR; Berens ME; Duckett Y; Morgan TM; Kute TE; Welander CE
    Cancer; 1990 Mar; 65(5):1055-61. PubMed ID: 2137365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: a phase II study.
    Freedman RS; Saul PB; Edwards CL; Jolles CJ; Gershenson DM; Jones LA; Atkinson EN; Dana WJ
    Cancer Treat Rep; 1986 Mar; 70(3):369-73. PubMed ID: 2937533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: therapeutic and endocrine effects in postmenopausal advanced breast cancer patients.
    Gasparini G; Canobbio L; Galligioni E; Fassio T; Brema F; Crivellari D; Villalta D; Di Fronzo G; Talamini R; Monfardini S
    Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1451-9. PubMed ID: 2960532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies.
    Vanderstappen D; Bonte J
    Eur J Gynaecol Oncol; 1992; 13(2):113-23. PubMed ID: 1534051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors.
    Fromm GL; Freedman RS; Fritsche HA; Atkinson EN; Scott W
    Cancer; 1991 Nov; 68(9):1885-9. PubMed ID: 1833046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses.
    Camaggi CM; Strocchi E; Canova N; Costanti B; Pannuti F
    Cancer Chemother Pharmacol; 1985; 14(3):229-31. PubMed ID: 3158448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
    Nemoto T; Patel JK; Rosner D; Dao TL; Halvorson H
    J Surg Oncol; 1989 Aug; 41(4):226-9. PubMed ID: 2526907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L; Durand M; Bonichon F; Chauvergne J
    Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate.
    Tatman JL; Freedman RS; Scott W; Atkinson EN
    Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1619-21. PubMed ID: 2531671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
    Noguchi S; Yamamoto H; Inaii H; Koyama H
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined chemo-hormone therapy in advanced ovarian cancer. Results of the 2d Austrian ovarian cancer study].
    Sevelda P
    Gynakol Rundsch; 1990; 30 Suppl 1():57-61. PubMed ID: 2150399
    [No Abstract]   [Full Text] [Related]  

  • 18. [The protective effect of medroxyprogesterone acetate in patients with ovarian cancer treated with chemotherapy].
    Enzelsberger H; Sevelda P; Salzer H
    Gynakol Rundsch; 1988; 28 Suppl 2():195-7. PubMed ID: 2976722
    [No Abstract]   [Full Text] [Related]  

  • 19. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?
    Malik ST; Slevin ML
    Br J Cancer; 1991 Mar; 63(3):410-1. PubMed ID: 1825918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.